source
- Foghorn Therapeutics cuts 40% of workforce after ending Lilly oncology partnershipFoghorn Therapeutics and Eli Lilly announced the end of their 2021 oncology collaboration. The partnership had focused on developing and commercializing cancer treatments. Following the terminatio…
- FDA issues warning letter to Fresenius Kabi over famotidine injection contaminationFDA inspectors spent three weeks at Fresenius Kabi's plant in Melrose Park, Illinois, and issued a warning letter after finding manufacturing deviations linked to patient adverse events. The issue…